Researchers at UTHealth have demonstrated in rats that transplanting genetically modified adult stem cells into an injured spinal cord can help restore the electrical pathways associated with movement. The results are published in today’s issue of the Journal of Neuroscience.
In spinal cord injury, demyelination, or the destruction of the myelin sheath in the central nervous system, occurs. The myelin sheath, produced by cells called oligodendrocytes, wraps around the axons of nerves and helps speed activity and insulate electrical conduction. Without it, the nerves cannot send messages to make muscles move.
The research team, led by Qilin Cao, M.D., principal investigator
Alan Lewis of the Juvenile Diabetes Research Foundation distinguishes type 1 and type 2 diabetes, and continues to explain how stem cells are being used today to develop new treatments for type 1 diabetes (a.k.a. juvenile diabetes). Human embryonic stem cells (hESC) are being differentiated to the beta (insulin producing) cells that type 1 diabetics lack, and are being transplanted , in animal models. Since type 1 diabetes is an auto-immune disease, the transplanted cells must be protect from destruction by the immune system. Currently, researchers are working towards that goal with encapsulating technologies and a “gentle” immuno-modulation. In
New Technology to Increase Efficacy of Adult Stem Cells in COPD Treatment
Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.
Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using photoceutical devices in treating COPD, it is believed stem cells can be focused on areas of the lungs where there is damage. Furthermore, being